Key result
FR 7534 increases ischemic myocardial blood flow ~70% during controlled systemic pressure.
Why the study?
The effects of different coronary vasodilators on transmural blood flow and contractile function in ischemic myocardium were not fully characterized.
Do different coronary vasodilators (FR 7534, nitroglycerin, dipyridamole) differentially affect regional myocardial blood flow and contractility during partial coronary occlusion in dogs?
Population
Anesthetized dogs with partial coronary artery occlusion
Comparison
FR 7534 vs nitroglycerin vs dipyridamole under hypotension and controlled aortic pressure
Design
Preclinical experimental study measuring blood flow and contractility
Follow-up
5 minutes infusion
Authors
Loading...
Hypothesis-generating for FR 7534 in myocardial ischemia; leaves open clinical translation pending human trials.
Do different coronary vasodilators (FR 7534, nitroglycerin, dipyridamole) differentially affect regional myocardial blood flow and contractility during partial coronary occlusion in dogs?
The novel calcium antagonist FR 7534 favorably alters the oxygen supply-demand balance in ischemic myocardium by increasing blood flow without increasing contractility when systemic pressure is maintained.
Gross et al. (1980) studied Ischemic myocardium. FR 7534 vs. Nitroglycerin and dipyridamole was evaluated on Transmural blood flow and contractile function in normal and ischemic myocardium. FR 7534 favorably affected oxygen supply-demand in ischemic myocardium by maintaining blood flow during hypotension and increasing flow by 70% during controlled systemic pressure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: